Escherichia coli O157: What every internist and gastroenterologist should know

被引：14

作者：

Bavaro M.F. ^{[1
]}

机构：

[1] Infectious Diseases Division, Naval Medical Center San Diego, San Diego, CA 92134

来源：

Current Gastroenterology Reports | 2009年 / 11卷 / 4期

关键词：

Hemolytic Uremic Syndrome; Fosfomycin; Rifaximin; Haemolytic Uraemic Syndrome; Shiga Toxin;

D O I：

10.1007/s11894-009-0044-0

中图分类号：

学科分类号：

摘要：

Infections with Escherichia coli O157:H7 have gained media attention in recent years because of cases associated with unusual sources (eg, produce and swimming pools). Although most adults recover without sequelae, children and the elderly are more likely to develop complications (eg, hemolytic uremic syndrome and death). The diagnosis typically has been made by culture; however, newer handheld immunoassays and polymerase chain reaction technology have led to more rapid detection of this important pathogen in stools, food, and water. Treatment is largely supportive; nonetheless, new methods to neutralize or bind toxin, such as probiotics, monoclonal antibodies, and recombinant bacteria, are showing promise to treat patients infected with E. coli O157:H7. The role of antibiotics in relation to this condition remains unclear. © Current Medicine Group, LLC 2009.

引用

页码：301 / 306

页数：5

共 54 条

[31]

Shima K., Kawamura N., Hinenoya A., Et al., Rapid culture-free identification and molecular typing of Shiga toxin-producing Escherichia coli by PCR-RFLP, Microbiol Immunol, 52, pp. 310-313, (2008)

[32]

Banatvala N., Griffin P.M., Greene K.D., Et al., The United States National Prospective Hemolytic Uremic Syndrome Study: Microbiologic, serologic, clinical, and epidemiologic findings, J Infect Dis, 183, pp. 1063-1070, (2001)

[33]

Cimolai N., Morrison B.J., Carter J.E., Risk factors for the central nervous system manifestations of gastroenteritisassociated hemolytic-uremic syndrome, Pediatrics, 90, pp. 616-621, (1992)

[34]

Ake J.A., Jelacic S., Ciol M.A., Et al., Relative nephroprotection during Escherichia coli O157:H7 infections: Association with intravenous volume expansion, Pediatrics, 115, (2005)

[35]

Scheiring J., Andreoli S.P., Zimmerhackl L.B., Treatment and outcome of Shiga-toxin associated hemolytic uremic syndrome (HUS), Pediatr Nephrol, 23, pp. 1749-1760, (2008)

[36]

Perez N., Spizzirri F., Rahman R., Et al., Steroids in the hemolytic uremic syndrome, Pediatr Nephrol, 12, pp. 101-104, (1998)

[37]

Afza M., Hawker J., Thurston H., Et al., An outbreak of Escherichia coli O157 gastroenteritis in a care home for the elderly, Epidemiol Infect, 134, pp. 1276-1281, (2006)

[38]

O'Brien S.J., Murdoch P.S., Riley A.H., Et al., A foodborne outbreak of Vero cytotoxin-producing Escherichia coli O157-H-phage type 8 in hospital, J Hosp Infect, 49, pp. 167-172, (2001)

[39]

Werber D., Mason B.W., Evans M.R., Salmon R.L., Preventing household transmission of shiga toxin-producing Escherichia coli O157 infection: Promptly separating siblings might be the key, Clin Infect Dis, 46, pp. 189-196, (2008)

[40]

Weightman N.C., Kirby P.J.G., Nosocomial Escherichia coli O157 infection, J Hosp Infect, 44, pp. 107-111, (2000)

← 1 2 3 4 5 6 →